ClinicalTrials.gg
Not yet recruitingNCT07505238Updated Apr 1, 2026

Informing Patients About Their Surgery's Environmental Impact: an Effective Pathway to Sustainable Healthcare?

An interventional study of Sustainability added to decision aid in Sustainability, Gallstone and Decision Aid, sponsored by University of Amsterdam. Not yet recruiting at 1 site in Netherlands. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by University of Amsterdam · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Sex
All
01

Study summary

The healthcare sector contributes significantly to climate change. Reducing the number of patients receiving resource-intensive procedures such as surgery can lower carbon emissions, particularly when two treatments with comparable clinical outcomes are available. Nevertheless, the impact of incorporating environmental considerations into patients' decision-making processes remains underexplored. The investigators examine how including information about the environmental impact of treatment options in a gallstone decision aid affects patients' real-life choice between surgery and the more sustainable alternative of conservative treatment. Moreover, the investigators examine whether factors such as severity of symptoms moderate the relation between sustainability information and patients' treatment choice. An exploratory vignette study informed the hypotheses that will be tested among actual patients with gallstones making actual treatment decisions. The results of this ecologically valid study have implications for both clinical practice and healthcare policy by offering insight into the effectiveness of pathways to include patients in the transition towards sustainable healthcare.

02

Conditions studied

  • Sustainability
  • Gallstone
  • Decision Aid
  • Decision Making ,Shared

Browse trials for

03

In context

Gallstones

199 studies on the registry are indexed under Gallstones; 35 are open to participants now.

This study's planned enrollment of 400 is above the median of 98 across 121 interventional studies indexed under Gallstones.

Browse Gallstones studies →

Lead sponsor

University of Amsterdam is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who were referred to three participating hospitals located across the Netherlands
  • Patients who received PatientPlus' gallstone decision aid in preparation for their surgical consultation

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Intervention condition

    Intervention condition, in which a decision aid includes a page with information about the environmental impact of surgical removal of the gallbladder.

    Behavioral: Sustainability added to decision aid

  • No intervention
    Control condition

    A control condition, which includes no information on sustainability in the decision aid.

Interventions

  • BehavioralSustainability added to decision aid

    The intervention decision aid includes a page with information about the environmental impact of surgical removal of the gallbladder, and a control condition, which includes no such information. Besides information about the environmental impact of gallbladder surgery, the intervention and control conditions will be identical. At the end of the decision aid patients will be debriefed in general phrasing (i.e., the aim of this study was to examine which factors affect treatment choice) to prevent influencing the actual decision. Approximately three months after patients received the decision aid, patients will receive an invitation via the PatientPlus portal to complete a survey in which the investigators inquire about their final treatment decision (first reminder after one week, second reminder after two weeks). At the end of this survey, patients will be debriefed about the aim of examining how information about the environmental impact of surgery affects treatment choice.

06

What researchers measure

Primary outcomes

  1. Treatment preference (surgery or wait-and-see)

    The primary outcome is treatment preference. Specifically, participants will indicate their treatment preference by selecting either the option 'Surgery' or 'Wait and see' (dichotomous variable)

    Time frame: baseline, pre-intervention

Secondary outcomes

  1. Treatment certainty

    Combination of treatment preference and certainty. Treatment certainty will be determined by answering the question 'How sure are you about what you want?' on a scale from 1 (Very uncertain) to 10 (Very certain). Treatment preference\*certainty will be calculated after data collection by multiplying treatment preference (coded as 1 for surgery and -1 for wait and see thus no surgery) with treatment certainty, resulting in a scale from -10 (Very certain about choosing no surgery) to +10 (Very certain about choosing surgery). Adding this continuous measure allows for capturing more nuanced differences between the intervention and control conditions compared to dichotomous measures.

    Time frame: baseline, pre-intervention

  2. Treatment decision

    Secondary outcome is treatment decision (number of patients that choose surgery and number of patients that choose wait-and-see)

    Time frame: Assessment 3 months after the participants receive the decision aid

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.

Of 58 non-industry interventional studies with no phase under Gallstones, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 58 studies reached it within 20 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Apr 1, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07505238
Lead sponsor
University of Amsterdam
Responsible party
Monique Chambon (Postdoctoral researcher, University of Amsterdam) — Principal investigator
First posted
Apr 1, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Apr 1, 2026

Study contacts

Monique Chambon, PhD
Contact
m.chambon@uva.nl
+31 (0)20 525 5340

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion